Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review

Area of Science:

• Cardiology
• Biomarker Research

Background:

• Heart failure (HF) affects millions globally, leading to high mortality and healthcare costs.
• Effective early diagnosis, prognostication, and therapy monitoring are critical for managing HF.
• Biomarkers play a vital role in addressing these challenges in HF management.

Purpose of the Study:

• To provide a comprehensive overview of current heart failure biomarkers.
• To examine the utility of various biomarkers in HF diagnosis, severity assessment, and treatment response.
• To highlight emerging biomarkers with potential for future HF management.

Main Methods:

• Review of existing research on heart failure biomarkers.
• Analysis of the diagnostic and prognostic capabilities of different biomarker categories.
• Identification of novel biomarkers and their potential applications in HF.

Main Results:

• Cardiac-specific biomarkers, including B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide, show significant promise for HF diagnosis and risk stratification.
• Markers related to oxidative stress, extracellular matrix, renal function, inflammation, and cardiac peptides aid in evaluating HF severity and prognosis.
• Emerging biomarkers such as microRNAs and insulin-like growth factor demonstrate potential for improving HF diagnosis and prognosis.

Conclusions:

• Current biomarkers offer valuable tools for HF diagnosis, risk stratification, and monitoring treatment efficacy.
• Further research into emerging biomarkers like microRNAs and insulin-like growth factor could enhance HF management strategies.
• A multi-biomarker approach may be essential for comprehensive heart failure patient care.